Paula Stefana Pintilei

Mrs. Paula Stefana Pintilei


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PPPaula Stefana Pintilei
Paula Stefana Pintilei
Roya BinaymotlaghRoya Binaymotlagh
Roya Binaymotlagh
Laura ChronopoulouLaura Chronopoulou
Laura Chronopoulou
Cleofe PalocciCleofe Palocci
Cleofe Palocci
Wound healing is a complex, multifaceted biological process that plays a vital role in recovery and overall quality of life. However, conventional wound care methods often prove insufficient, resulting in delayed healing, higher infection risk, and other complications. In response, biomaterials—especially hydrogels—have gained attention for their advanced wound management capabilities, which support wound healing by maintaining moisture, mimicking the extracellular matrix (ECM), and enabling targeted drug delivery triggered by wound-specific signals. They frequently carry antimicrobial or anti-inflammatory agents, promote blood vessel and nerve regeneration, and are biocompatible with customizable properties suited to different healing stages. Natural hydrogels, derived from polysaccharides, proteins, and peptides, offer several advantages over synthetic options, including inherent bioactivity, enzymatic degradability, and cell-adhesive qualities that closely resemble the native ECM. These features facilitate cell interaction, modulate inflammation, and speed up tissue remodeling. Moreover, natural hydrogels can be engineered as delivery systems for therapeutic agents like antimicrobial compounds, nanoparticles, growth factors, and exosomes. This review discusses recent advances in the use of natural hydrogels as multifunctional wound dressings and delivery platforms, with a focus on their composition, mechanisms of action, and potential for treating chronic and infected wounds by incorporating antimicrobial and regenerative additives such as silver and zinc oxide nanoparticles.

8 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FHFarid Hajareh Haghighi
Farid Hajareh Haghighi
Roya BinaymotlaghRoya Binaymotlagh
Roya Binaymotlagh
PPPaula Stefana Pintilei
Paula Stefana Pintilei
Laura ChronopoulouLaura Chronopoulou
Laura Chronopoulou
Cleofe PalocciCleofe Palocci
Cleofe Palocci
Polyhydroxyalkanoates (PHAs), a family of biodegradable polyesters produced through microbial fermentation of carbon-rich residues, are emerging as attractive alternatives to petroleum-based plastics. Their appeal lies in their exceptional biocompatibility, inherent biodegradability, and tunable physicochemical properties across diverse applications. These materials are environmentally friendly not just at the end of their life, but throughout their entire production–use–disposal cycle. This mini-review presents an update on the expanding biomedical relevance of PHAs, with emphasis on their utility in tissue engineering and drug delivery platforms. In addition, current clinical evaluations and regulatory frameworks are briefly discussed, underscoring the translational potential of PHAs in meeting unmet medical needs. As the healthcare sector advances toward environmentally responsible and patient-focused innovations, PHAs exemplify the convergence of waste valorization and biomedical progress, transforming discarded resources into functional materials for repair, regeneration, and healing.

31 July 2026 in Macromol
Verified
Journal Article
Open access
PDF file
PPPaula Stefana Pintilei
Paula Stefana Pintilei
Roya BinaymotlaghRoya Binaymotlagh
Roya Binaymotlagh
FHFarid Hajareh Haghighi
Farid Hajareh Haghighi
Laura ChronopoulouLaura Chronopoulou
Laura Chronopoulou
Cleofe PalocciCleofe Palocci
Cleofe Palocci
Nanomedicine-based liposomal delivery systems are gaining increasing attention as advanced therapeutic platforms for managing ocular infections associated with antimicrobial resistance (AMR) and biofilm formation. The primary objective of this review is to critically evaluate the potential of liposomal drug delivery systems for improving the treatment of antimicrobial-resistant and biofilm-associated ocular infections by integrating current knowledge on antimicrobial resistance mechanisms, biofilm-targeted therapeutic strategies, and advances in liposomal formulations, while also identifying the major limitations, translational challenges, and knowledge gaps in this rapidly evolving field. Traditional ocular antimicrobial treatments are frequently limited by poor drug penetration, short precorneal residence time, low bioavailability, systemic side effects, and inadequate activity against resistant microorganisms and biofilm-embedded pathogens. This review provides a comprehensive overview of different liposomal systems, including conventional, cationic, polyethylene glycol (PEG)-modified, deformable, and stimulus-responsive liposomes, and discusses their advantages in ophthalmic drug delivery, such as enhanced corneal permeation, prolonged drug retention, controlled release, improved biocompatibility, and reduced ocular toxicity. The review further examines the mechanisms through which liposomes help overcome AMR, including improved epithelial transport, membrane disruption, intracellular drug delivery, efflux pump evasion, and enhanced antimicrobial efficacy. In addition, liposomal approaches targeting ocular biofilms are explored, focusing on improved biofilm penetration and the delivery of anti-biofilm agents such as antibiotics, enzymes, quorum-sensing inhibitors, and antimicrobial peptides. Current evidence from in vitro and in vivo ocular infection models is summarized together with disease-specific applications in keratitis, endophthalmitis, and contact lens-related infections. The article also compares liposomes with other ocular nanocarriers and addresses important considerations related to safety, stability, sterilization, large-scale production, and regulatory translation. In addition to highlighting recent advances, this review critically discusses the current limitations of liposomal formulations, the major barriers to clinical translation, and the key knowledge gaps that should be addressed to facilitate the future development and successful clinical application of these systems. Finally, emerging directions including ligand-targeted and stimulus-responsive liposomes, AI-driven formulation development, personalized nanotherapy, and gene therapy combinations are discussed as promising future strategies for combating resistant ocular infections.